IGC Pharma Strengthens CALMA Trial Through Caregiver Outreach
POTOMAC, Maryland, April 28, 2026 IGC Pharma, Inc. has announced expanded caregiver engagement efforts as its Phase 2 CALMA...
Phase 2 clinical trial
Advertisement
Quantum BioPharma Submits IND for Lucid-MS Trial
TORONTO, April 1, 2026 Quantum BioPharma Ltd. announced the submission of an Investigational New Drug (IND) application to the...
MiNK Therapeutics Highlights Phase II iNKT Therapy at AACR
NEW YORK, April 3, 2026 MiNK Therapeutics announced that new Phase II clinical trial data for its investigational iNKT...
Sanofi Rilzabrutinib Wins Japan Orphan Status
Paris, March 2, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug...
IGC Pharma Expands Phase 2 CALMA Alzheimer’s Trial
POTOMAC, Md., Feb. 9, 2026 — IGC Pharma, Inc. announced the expansion of its ongoing Phase 2 CALMA clinical...
Advertisements
Tau Immunotherapy AADvac1 Enters Landmark AD Trial
SAN FRANCISCO, Calif., Feb. 4, 2026 — Axon Neuroscience announced that its active tau immunotherapy AADvac1 has been selected...
Edgewise Reports Phase 2 Safety Progress for EDG-7500 in HCM
BOULDER, Colorado | December 24, 2025 — Edgewise Therapeutics announced the completion of Parts B and C of the...
Kiora Pharmaceuticals Advances Dual Phase 2 Retinal Trials with FDA-Backed Innovation
Dateline — Encinitas, California, November 8, 2024:Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its third-quarter 2024 results alongside significant progress...
Advertisement
